Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 30360. Отображено 100.
05-01-2012 дата публикации

Novel tetrahydro-quinoline derivatives

Номер: US20120004218A1
Принадлежит: Hoffmann La Roche Inc

A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A 1 to A 3 and R 1 to R 10 have the significance given in claim 1 , can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.

Подробнее
12-01-2012 дата публикации

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Номер: US20120010239A1
Автор: Ulf Tomas Fristedt
Принадлежит: Teva Pharmaceutical Industries LTD

The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.

Подробнее
12-01-2012 дата публикации

Acetylene derivatives having mglur 5 antagonistic activity

Номер: US20120010263A1
Принадлежит: Individual

The invention provides compounds of formula I wherein n, A, R, R′, R″, R O , X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.

Подробнее
12-01-2012 дата публикации

Modulation of anxiety through blockade of anandamide hydrolysis

Номер: US20120010283A1

Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

Подробнее
19-01-2012 дата публикации

Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof

Номер: US20120016129A1
Принадлежит: MSN Laboratories Pvt Ltd

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

Подробнее
26-01-2012 дата публикации

Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof

Номер: US20120022102A1
Принадлежит: Cadila Healthcare Ltd

The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
08-03-2012 дата публикации

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Номер: US20120058945A1

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.

Подробнее
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
12-04-2012 дата публикации

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Номер: US20120088746A1
Принадлежит: PFIZER INC

Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Подробнее
19-04-2012 дата публикации

Organic Compounds Having Cooling Properties

Номер: US20120095042A1
Автор: Stefan Michael Furrer
Принадлежит: Givaudan SA

Provided are compounds of formula (I) wherein m is 0, 1 or 2; R I is a mono- or bicyclic heterocyclic ring system including one, two or three heteroatoms selected from nitrogen, sulphur and oxygen; R 2 is selected from hydrogen, methyl and ethyl; I) R 3 is hydrogen, methyl, or ethyl; and R 4 and R 5 are independently selected from ethyl and isopropyl; and R 3 , R 4 and R 5 together have at least 6 carbon atoms: or II) any two or all of R 3 , R 4 and R 5 form together with the carbon atom to which they are attached 3-para-menthyl, bornyl, or adamantyl; having cooling properties, their use as cooling agent and compositions including them.

Подробнее
19-04-2012 дата публикации

Triglyceride-lowering agent and hyperinsulinism-ameliorating agent

Номер: US20120095043A1
Автор: Taro Aoki, Toru Yokoyama
Принадлежит: Kowa Co Ltd, Nissan Chemical Corp

The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.

Подробнее
10-05-2012 дата публикации

Compounds having antiparasitic or anti-infectious activity

Номер: US20120115904A1

Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R 1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R 2 is methyl or haloalkyl; R 4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R 3 is aliphatic, aryl, aralkyl, or alkylaryl; and R 5 , R 6 , R 7 and R 8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO 2 R 10 , wherein R 10 is H, alkyl, amino or haloalkyl; provided that in formula I, R 5 and R are not both H or R 6 is not H or methoxy; and in formula II that if R 4 is carbonyldioxy then R 7 is not methoxy.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
10-05-2012 дата публикации

Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders

Номер: US20120115931A1
Принадлежит: Individual

The invention relates to a method for treating and/or preventing obesity and/or obesity-related disorders by administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression.

Подробнее
24-05-2012 дата публикации

Cadherin-11 inhibitors and methods of use thereof

Номер: US20120128693A1
Принадлежит: GEORGETOWN UNIVERSITY

Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.

Подробнее
28-06-2012 дата публикации

Quinoline derivatives as pi3 kinase inhibitors

Номер: US20120165321A1
Принадлежит: GlaxoSmithKline LLC

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Подробнее
28-06-2012 дата публикации

Quinoline derivatives as anti-cancer agents

Номер: US20120165370A1
Принадлежит: Hong Kong Polytechnic University HKPU

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

Подробнее
19-07-2012 дата публикации

Quinolines and Their Therapeutic Use

Номер: US20120184579A1
Принадлежит: Individual

Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R 1 is halogen or cyano; R 2 is hydrogen or methyl; R 3 and R 4 are independently —OR 6 , C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R 5 is hydrogen or halogen; R 6 is C 1 C 6 alkyl or C 3 -C 6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH 2 —, —S—, or —O—; one of Y and Y 1 is hydrogen and the other is OR 6 , —C(═O)R 7 , NR 8 SO 2 R 6 or a heterocyclic group selected from those referred to in the specification; and R 6 , R 7 and R 8 are as defined in the specification.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
23-08-2012 дата публикации

Synthesis of optically active intermediate for the preparation of montelukast

Номер: US20120215002A1
Автор: Laurent Lefort
Принадлежит: DSM IP ASSETS BV

The present invention relates to the synthesis of optically active alcohols by means of enantioselective hydrogenation of ketones in biphasic systems. In particular the present invention relates to the synthesis of an optically active alcohol of general formula (1).

Подробнее
30-08-2012 дата публикации

Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators

Номер: US20120220627A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to substituted 2-amino-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Подробнее
30-08-2012 дата публикации

Enantioselective preparation of quinoline derivatives

Номер: US20120220775A1
Принадлежит: Individual

A process for preparing 8-substituted oxy-5-((R)-2-halo-1-hydroxy-ethyl)-(1H)-quinolin-2-ones or acceptable solvates thereof. The process involves reacting a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((R)-2-halo-1-hydroxy-ethyl)-(1H)-quinolin-2-one, said chiral agent having a formula I or II wherein M, L, X, R 1 , R 2 and R 3 have the meanings as indicated in the specification.

Подробнее
06-09-2012 дата публикации

Compositions and methods useful for treating diseases

Номер: US20120225851A1
Принадлежит: Eutropics Pharmaceuticals Inc

The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Подробнее
25-10-2012 дата публикации

Adamantyl diamide derivatives and uses of same

Номер: US20120270873A1
Принадлежит: H Lundbeck AS

The present invention provides adamantyl-diamide derivatives of formula (I): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

Подробнее
08-11-2012 дата публикации

New heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the app metabolism occurs

Номер: US20120283256A1
Принадлежит: Individual

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Подробнее
15-11-2012 дата публикации

Novel compounds with high therapeutic index

Номер: US20120289471A1
Автор: V. Ravi Chandran
Принадлежит: Signature R&D Holdings LLC

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Подробнее
29-11-2012 дата публикации

Thiolactams and uses thereof

Номер: US20120302551A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention provides compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Подробнее
13-12-2012 дата публикации

Quinolinone derivatives and their pharmaceutical compositions

Номер: US20120316142A1
Принадлежит: Individual

Compounds of formula I in salt or solvate form, wherein W, R x , R y , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 and A have the meanings as indicated in the specification, are useful for treating diseases mediated by the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Подробнее
13-12-2012 дата публикации

Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Номер: US20120316179A1
Принадлежит: Otsuka Pharmaceutical Co Ltd

The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Подробнее
20-12-2012 дата публикации

Process and intermediate compounds useful in the preparation of statins

Номер: US20120323011A1
Принадлежит: Redx Pharna PLC

There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein R a represents an alkyl group, such as a C 1-16 alkyl group, and preferably an isopropyl group; R b represents an aryl group, preferably a 4-fluorophenyl group; R c represents hydrogen, a protecting group or an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO 2 R e group where R e is an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group.

Подробнее
17-01-2013 дата публикации

Lithium metal quinolates and process for preparation thereof as good emitting, interface materials as well as n-type dopent for organic electronic devices

Номер: US20130015431A1
Принадлежит: Individual

Invention relates to a single step preparation of alkali metal quinolate of general formula 1 wherein M=Lithium, sodium or potassium; R═H, alkyl (C1-C6), alkoxy, aryl, aryloxy, amino, amido or halogen (Cl, F, Br, I) which is substituted or unsubstituted with direct reaction of metal with 8-hydroxyquinoline. Substituted 8-hydroxyquinoline optionally have at least one substituent selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, amino, amido at 2, 5 or 7 position. Halogen substituted 8-hydroxyquinolates are also prepared from this method in the yield of 90-95% from polar solvents like acetonitrile. These complexes are useful as light emitting and electron injecting materials in organic electronic devices. Also the doping of these materials in electron transport materials improves their electron mobility.

Подробнее
17-01-2013 дата публикации

Aminomethyl quinolone compounds

Номер: US20130018043A1
Принадлежит: Individual

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Подробнее
21-03-2013 дата публикации

Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

Номер: US20130072522A1
Принадлежит: Vertex Pharmaceuticals Inc

The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.

Подробнее
21-03-2013 дата публикации

Method for preparing an intermediate of pitavastatin or of the salt thereof

Номер: US20130072688A1
Автор: Hyun-Gyu Kim, Seo-Jin Lee
Принадлежит: H L GENOMICS

The present invention relates to a method for preparing (4R,6S)-(E)-6-[2-(2-cyclopropyl)-4-(4-fluorophenyl)quinolin-3-yl)-vinyl-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid ester derivative, which is an intermediate of pitavastatin or of the salt thereof, into a crystalline solid form. In addition, the present invention relates to a novel solvate of the intermediate, and to a method for preparing pitavastatin or the salt thereof using the intermediate.

Подробнее
28-03-2013 дата публикации

NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20130076604A1
Принадлежит: CANON KABUSHIKI KAISHA

Provided are a novel organic compound appropriate for emission of green light and an organic light-emitting device including the organic compound. Provided is a substituted or unsubstituted indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene appropriate for emission of green light. The substituents of the indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group. 2. The organic compound according to claim 1 , wherein Rto Rare each independently selected from a hydrogen atom and a substituted or unsubstituted aryl group.4. An organic light-emitting device comprising:an anode;a cathode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an organic compound layer disposed between the anode and the cathode, the organic compound layer containing the organic compound according to .'}5. An organic light-emitting device comprising:an anode;a cathode; and{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'an organic compound layer disposed between the anode and the cathode, the organic compound layer containing the organic compound according to .'}6. The organic light-emitting device according to claim 4 , wherein the organic compound layer is a light-emitting layer.7. The organic light-emitting device according to claim 6 , wherein the organic light-emitting device emits green light.8. A display apparatus having a plurality of pixels claim 4 , each including the organic light-emitting device according to and a switching device connected to the organic light-emitting device.9. An image input apparatus comprising:an image input unit configured to input an image; and{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'a display unit configured to display the image, the display unit having a plurality of pixels, each ...

Подробнее
28-03-2013 дата публикации

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

Номер: US20130079367A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 126-. (canceled)27. A method of treating or lessening the severity of a disease in a patient , wherein said disease is selected from cystic fibrosis , asthma , smoke induced COPD , chronic bronchitis , rhinosinusitis , constipation , pancreatitis , pancreatic insufficiency , male infertility caused by congenital bilateral absence of the vas deferens (CBAVD) , mild pulmonary disease , idiopathic pancreatitis , allergic bronchopulmonary aspergillosis (ABPA) , liver disease , hereditary emphysema , hereditary hemochromatosis , coagulation-fibrinolysis deficiencies , such as protein C deficiency , Type 1 hereditary angioedema , lipid processing deficiencies , such as familial hypercholesterolemia , Type 1 chylomicronemia , abetalipoproteinemia , lysosomal storage diseases , such as I-cell disease/pseudo-Hurler , mucopolysaccharidoses , Sandhof/Tay-Sachs , Crigler-Najjar type II , polyendocrinopathy/hyperinsulemia , Diabetes mellitus , Laron dwarfism , myleoperoxidase deficiency , primary hypoparathyroidism , melanoma , glycanosis CDG type 1 , congenital hyperthyroidism , osteogenesis imperfecta , hereditary hypofibrinogenemia , ACT deficiency , Diabetes insipidus (DI) , neurophyseal DI , neprogenic DI , Charcot-Marie Tooth syndrome , Perlizaeus-Merzbacher disease , neurodegenerative diseases such as Alzheimer's disease , Parkinson's disease , amyotrophic lateral sclerosis , progressive supranuclear plasy , Pick's disease , several polyglutamine neurological disorders such as Huntington's , spinocerebullar ataxia type I , spinal and bulbar muscular atrophy , dentatorubal pallidoluysian , and myotonic dystrophy , as well as spongiform encephalopathies , such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect) , Fabry disease , ...

Подробнее
28-03-2013 дата публикации

FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES

Номер: US20130079524A1
Принадлежит:

The present invention relates N-cycloalkyl-N-bicyclic-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group; T represents O, S, N-R, N—OR, N—NRRor N—CN; Zrepresents a C-C-cycloalkyl group; X represents N or a CZand Z; Z; Land Lrepresent various substituents; their process of preparation; preparation intermediate compounds; their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 116-. (canceled)18. The compound of wherein Zis a cyclopropyl.19. The compound of wherein Zis a non-substituted cyclopropyl.20. The compound of wherein Zis a hydrogen atom.21. The compound of wherein Lis CZZ.22. The compound of wherein Lis CZZand m is 1 or 2.23. The compound of wherein Zand each Zare independently selected from the group consisting of a hydrogen atom; a halogen atom; C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; C-C-alkoxy; and C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different. The present invention relates to N-cycloalkyl-N-bicyclic-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.In international patent application WO-2007/014290 certain N-substituted-N-bicyclic-carboxamide or thiocarboxamide derivatives are generically embraced in a broad disclosure of numerous compounds of the following formula:wherein Wcan represent oxygen or sulphur; A can represent NH or CH; Rcan represent a phenyl or heterocyclic ring; G can represent a 5-membered heterocyclic ring, ...

Подробнее
04-04-2013 дата публикации

COMPOUNDS DERIVED FROM ARTESUNATE, PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION AND USE OF THE RESPECTIVE MEDICINE

Номер: US20130085159A1
Принадлежит: FUNDAÇÃO OSWALDO CRUZ

The present invention refers to new compounds represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III). The relation X to Y may vary from 1:1 to 1:7. The radicals R, R, R, R, R, and Rin formula (II) are represented by: R═H, CF, CH, OCH, NH, halogen; R═H, CH, NH, halogen, NH—CHCH(CH)N(CH)(CHCHOH), CH(OH)-2(CHN), NH—R—N—(CH); R═H, m-OCHCF, NH; R═H, CH, OCH, NH, halogen; R═H, CH, CF, NH, halogen; R═H, CF, CH, NH, halogen, NH—R—N—(CH), NHCH(CH) (CH)NH; R═(CH), (CH), CHCHCH, (CH), (CH), CHCH(CH), (CH), (CH), (CH), (CH); R═CHCH(CH), CHCH(CH)CHCH, (CH), (CH), (CH), (CH)O(CH). This invention also refers to a process of preparation of these compounds (formula I), and antiparasitic pharmaceutical compositions thereof. 2. Compounds according to claim 1 , characterized by the fact that R═H; R═NHCH(CH)(CH)N(CH); R═R═R═H and R═Cl; and the relation X to Y equals 1:1.3. Compounds according to claim 1 , characterized by the fact that R═CF3; R═CH(OH)-2-(CHN); R═R═R═H and R═CFand the relation X to Y equals 1:1.4. Compounds according to claim 1 , characterized by the fact that R═R═R═R═H; R═OCHand R═NHCH(CH)(CH)NH; and X to Y equals 1:2.5. Preparation process of artesunate derived compounds claim 1 , as defined by claim 1 , characterized by the fact it comprises the following stages:a) solubilization of quinoline, represented by the general formula II, as a free base form in organic solvents;b) solubilization of artesunate, represented by the general formula III, in organic solvents;c) addition of the artesunate solution (stage b) to the quinoline solution (stage a) in order to obtain derivatives of artesunate salts of quinolines;d) solvent evaporation for salt precipitation;e) salt filtration in order to obtain derivatives of artesunate salts of quinolines as a solid product. Its effectiveness ranges from 80 to 96%.6. Preparation process of artesunate derivatives according to claim 5 , characterized by ...

Подробнее
18-04-2013 дата публикации

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

Номер: US20130096122A1
Принадлежит: Gilead Sciences, Inc.

The present invention relates to sodium channel inhibitors of Formula I: 2. The compound of claim 1 , wherein Xand Xare both —CH═.3. The compound of claim 2 , wherein Ris hydrogen or alkyl of 1-6 carbon atoms optionally substituted by hydroxy claim 2 , —C(O)R claim 2 , trifluoromethyl claim 2 , alkoxy of 1-6 carbon atoms claim 2 , or phenyl optionally substituted by —C(O)R.4. The compound of claim 3 , wherein R claim 3 , R claim 3 , and Rare hydrogen or lower alkyl of 1-6 carbon atoms.5. The compound of claim 4 , wherein Ris phenyl optionally substituted by 1 or 2 substituents independently selected from halo claim 4 , trifluoromethyl claim 4 , trifluoromethoxy claim 4 , cyano claim 4 , or —C(O)R claim 4 ,6. The compound of claim 5 , wherein Ris hydrogen claim 5 , R claim 5 , R claim 5 , R claim 5 , and Rare hydrogen claim 5 , Ris methoxy claim 5 , and Ris 6-(4-chlorophenyl) claim 5 , namely 6-(4-chlorophenyl)-7-methoxy-3 claim 5 ,4-dihydroquinolin-2(1H)-one.7. The compound of claim 5 , wherein Ris 2-methoxyethyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(4-trifluoromethylphenyl) claim 5 , namely 1-(2-methoxyethyl)-6-(4-(trifluoromethyl)phenyl)-3 claim 5 ,4-dihydroquinolin-2(1H)-one.8. The compound of claim 5 , wherein Ris carboxymethyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(4-trifluoromethoxyphenyl) claim 5 , namely 2-(2-oxo-6-(4-(trifluoromethoxy)phenyl)-3 claim 5 ,4-dihydroquinolin-1(2H)-yl)acetic acid.9. The compound of claim 5 , wherein Ris hydrogen claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(3-fluorophenyl) claim 5 , namely 6-(3-fluorophenyl)-3 claim 5 ,4-dihydroquinolin-2(1H)-one.10. The compound of claim 5 , wherein Ris benzyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(2 claim 5 ,4-difluorophenyl) claim 5 , namely 1-benzyl-6-(2 claim 5 ,4-difluorophenyl)-3 claim 5 ,4-dihydroquinolin-2( ...

Подробнее
18-04-2013 дата публикации

NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT

Номер: US20130096138A1
Принадлежит: AVIXGEN INC.

Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Having high inhibitory activity against HIV, the thiourea or urea derivatives can be effectively used in the prophylaxis or therapy of AIDS. 3. The thiourea or urea derivative claim 1 , or the pharmaceutically acceptable salt of claim 1 , wherein the thiourea or urea derivative is selected from the group consisting of:1-(4-tert-butyl-benzoyl)-3-(5-hydroxy-naphthalen-1-yl)-thiourea1-(4-tert-butyl-benzoyl)-3-(3-dimethylamino-propyl)-thiourea,1-(4-tert-butyl-benzoyl)-3-(3-dimethylamino-2,2-dimethyl-propyl)-thiourea,4-tert-butyl-N-(4-ethyl-piperazin-1-carbothioyl)-benzoamide,3-(4-tert-butyl-benzoyl)-1-(2-diethylamino-ethyl)-1-methyl-thiourea,3-(4-tert-butyl-benzoyl)-1-(2-dimethylamino-ethyl)-1-methyl-thiourea,1-(4-tert-butyl-benzoyl)-3-(4-diethylamino-1-methyl-butyl)-thiourea,1-(4-tert-butyl-benzoyl)-3-(4-methyl-benzyl)-thiourea,1-(4-tert-butyl-benzoyl)-3-(2-methyl-benzyl)-thiourea,1(4 tert-butyl-benzoyl)-3-(3-propylamino-propyl)-thiourea,1(4 tert-butyl-benzoyl)-3-phenethyl-thiourea,1-(4-tert-butyl-benzoyl)-3-(4-chloro-benzyl)-thiourea,1-(4-tert-butyl-benzoyl)-3-(3-chloro-benzyl)-thiourea,1-(4-tert-butyl-benzoyl)-3-(naphthalen-2-ylmethyl)-thiourea,4-tert-butyl-N-[4-(4-fluoro-phenyl)-piperazin-1-carbothioyl]-benzamide,1-(4-tert-butyl-benzoyl)-3-cyclohexyl-thiourea,1-(4-tert-butyl-benzoyl)-3-(2-fluoro-benzyl)-thiourea,1-benzoyl-3-(naphthalen-2-ylmethyl)-thiourea,1-benzoyl-3-[2-(4-chloro-phenyl)-ethyl]-thiourea,1-benzoyl-3-(4-diethylamino-1-methyl-butyl)-thiourea,3-benzoyl-1-(2-diethylamino-ethyl)-1-methyl-thiourea,N-(4-ethyl-piperazin-1-carbothioyl)-4-methyl-benzamide,1-cyclohexyl-3-(4-methyl-benzoyl)-thiourea,1-(4-chloro-benzyl)-3-(4-methyl-benzoyl)-thiourea,1-(3-dimethylamino-propyl)-3-(4-methyl-benzoyl)-thiourea,1-(4- ...

Подробнее
18-04-2013 дата публикации

Quinoline derivatives as fungicides

Номер: US20130096156A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

Compounds of the general formula (I) wherein the substituents are as defined in claim 1 , are useful as fungicides.

Подробнее
18-04-2013 дата публикации

Inhibitors of human 12-lipoxygenase

Номер: US20130096159A1

Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R 1 , R 2 , R 3 , and R 4 are as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.

Подробнее
18-04-2013 дата публикации

PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF

Номер: US20130096303A1
Принадлежит:

The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R—N—O—Rmoiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof. 3. The process of claim 2 , wherein the acid is selected from the group consisting of hydrochloric acid claim 2 , sulfuric acid claim 2 , phosphoric acid claim 2 , nitric acid claim 2 , acetic acid claim 2 , formic acid claim 2 , sulfonic acid claim 2 , and a mixture thereof.5. The process of claim 4 , wherein the hydrolyzing is performed by reacting the compound of Formula 6 with an alkali metal hydroxide or an alkaline earth metal hydroxide.6. The process of claim 4 , wherein the acid is selected from the group consisting of hydrochloric acid claim 4 , sulfuric acid claim 4 , phosphoric acid claim 4 , nitric acid claim 4 , acetic acid claim 4 , formic acid claim 4 , sulfonic acid claim 4 , and a mixture thereof.7. The process of claim 1 , wherein Rand Rare independently methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , isopropyl claim 1 , or phenyl.16. The process of claim 15 , wherein the reacting is performed in the presence of a base selected from the group consisting of sodium C˜Calkoxide claim 15 , potassium C˜Calkoxide claim 15 , sodium carbonate claim 15 , potassium carbonate claim 15 , lithium carbonate claim 15 , cesium carbonate claim 15 , sodium bicarbonate claim 15 , potassium bicarbonate claim 15 , potassium phosphate claim 15 , 1 claim 15 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) claim 15 , 1 claim 15 ,4-diazabicyclo[2.2.2]octane (DABCO) claim 15 , 1 claim 15 ,5-diazabicyclo[4.3.0]non-5-ene (DBN) claim 15 , pyridine claim 15 , dimethylaminopyridine claim 15 , triethylamine claim 15 , lithium bis(trimethylsilyl)amide ...

Подробнее
18-04-2013 дата публикации

Method of synthesis of ferroquine by convergent reductive amination

Номер: US20130096306A1
Принадлежит: SANOFI SA

The invention relates to a method of synthesis of ferroquine of formula (F) or of its metabolite of formula (Fm): comprising a reaction of reductive amination, said reaction comprising: (i) a stage of condensation of an aldehyde-amino ferrocene of formula (III), in which R represents a hydrogen atom or a methyl group, with 7-chloroquinolin-4-amine as shown below, followed by (ii) a stage of reduction of the product of condensation obtained in the preceding stage and (iii) then a stage of hydrolysis of the reaction mixture in the presence of an aqueous solution of ammonia or of citric acid.

Подробнее
25-04-2013 дата публикации

Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste

Номер: US20130101684A1
Принадлежит: CHROMOCELL CORPORATION

The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product. 710.-. (canceled)1355.-. (canceled)5661112. The composition of any one of - claims 1 , or claims 1 , further comprising a bitter tastant.576111256. The composition of any one of - claims 1 , claims 1 , or claims 1 , wherein the composition further comprises one or more components selected from the group consisting of: NaCl claims 1 , sodium lactate and sugar.58611125657. The composition of any one of - claims 1 , claims 1 , claims 1 , or claims 1 , wherein the composition is found in a food product or a consumer product.5961112. The composition of any one of - claims 1 , or claims 1 , wherein the composition further comprises a pharmaceutically active ingredient claims 1 , and optionally claims 1 , a bitter tastant.60. The composition of claim 59 , wherein the pharmaceutically active ingredient is bitter.61. The composition of or claim 59 , wherein the pharmaceutically active ingredient or bitter tastant is a potassium salt.62. The composition of any one of claim 59 , or claim 59 , wherein the bitter tastant is a potassium salt claim 59 , and wherein the potassium salt is potassium chloride or potassium lactate.6361112. A method of use of the composition of any one of - claims 1 , or claims 1 , wherein the method comprises:(a) providing a comestibly acceptable carrier; and{'claim-ref': {'@idref': 'CLM-00001', 'claims 1'}, 'b': '8', '(b) adding to the comestibly acceptable carrier, a composition as described in any of - or combinations thereof.'}64. The method of claim 63 , wherein the method further comprises adding a bitter tastant to the comestibly acceptable carrier.65. The ...

Подробнее
25-04-2013 дата публикации

BIARYL OXYACETIC ACID COMPOUNDS

Номер: US20130102609A1
Принадлежит: LIGAND PHARMACEUTICALS INC.

The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general formula I: 2. A compound or salt according to wherein R claim 1 , R claim 1 , Rand Rare each independently selected from hydrogen and methyl.3. (canceled)4. A compound or salt according to claim 1 , wherein Ris selected from hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl and isopropyl.5. (canceled)6. A compound or salt according to claim 1 , wherein Ris selected from aryl and heteroaryl claim 1 , each optionally substituted with one to four substituents independently selected from halogen claim 1 , cyano claim 1 , (C-C) haloalkyl claim 1 , (C-C) alkoxy claim 1 , (C-C) haloalkoxy claim 1 , (C-C) alkyl claim 1 , and (C-C) alkylsulfonyl.9. A compound or salt according to claim 8 , wherein Ris selected from hydrogen claim 8 , methyl claim 8 , fluoro claim 8 , chloro claim 8 , cyano claim 8 , —CFand methoxy; and Ris selected from hydrogen claim 8 , fluoro claim 8 , chloro claim 8 , methyl claim 8 , methoxy claim 8 , cyano claim 8 , —CFand —SOCH.10. A compound or salt according to wherein Rand Rare each independently selected from fluoro claim 9 , chloro claim 9 , methoxy and hydrogen.11. (canceled)13. A compound or salt according to wherein Ris selected from naphthyl claim 6 , pyridinyl and quinolinyl claim 6 , each optionally substituted with one to four substituents independently selected from halogen claim 6 , cyano claim 6 , (C-C) haloalkyl claim 6 , (C-C) alkoxy claim 6 , (C-C) haloalkoxy claim 6 , (C-C) alkyl and alkylsulfonyl.14. A compound or salt according to claim 1 , wherein Rand Rare each hydrogen.15. A compound or salt according to claim 1 , wherein A is selected from phenyl claim 1 , pyridinyl claim 1 , benzimidazolyl claim 1 , quinolinyl claim 1 , indolyl claim 1 , pyrimidinyl and imidazopyridinyl.16. A compound ...

Подробнее
25-04-2013 дата публикации

Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers

Номер: US20130102630A1
Принадлежит: BIOPHARMED

The invention relates to compounds of the aminated hydroxyquinoline type capable of preventing the migration of metastases or tumoral cells. Such compounds are useful for treating cancers.

Подробнее
25-04-2013 дата публикации

NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES

Номер: US20130102631A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

The present invention provides compounds of formula (I) wherein R, A, X, Y, Y, Y, G, G, Gand p are as defined in the claims. The invention further provides intermediates used in the preparation of these compounds, to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi. 2. A compound according to wherein Rrepresents hydrogen claim 1 , (C-Calkyl)OC claim 1 , C-Calkyl claim 1 , phenyl or pyridyl claim 1 , wherein the alkyl claim 1 , phenyl and pyridyl are optionally substituted by one or more groups independently selected from halogen claim 1 , CN claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Ccycloalkyl and a 5- or 6-membered heterocycle containing one to three nitrogen atoms;{'sup': '1', 'Arepresents cycle A-2, A-4, or A-5;'}{'sup': 3', '6', '7', '8', '9', '11', '11', '12, 'sub': 1', '8', '3', '8', '2', '8', '2', '8', '1', '8', '1', '8', '1', '8', '2', '2', '2', '2', '1', '4', '1', '4', '1', '4', '1', '4, 'R, R, R, Rand Rindependently of one another represent hydrogen, halogen, CN, C-Calkyl, C-Ccycloalkyl, C-Calkenyl, C-Calkynyl, phenyl, a 5- or 6-membered heterocycle containing one to three nitrogen atoms, OR, SH, C-C-alkylthio, C-C-alkylsulphinyl, C-C-alkylsulphonyl, COR, CON(R), or wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl and heterocycle are optionally substituted by one or more groups independently selected from halogen, CN, NH, NO, OH, C-Calkyl, C-Chaloalkyl, C-Calkoxy and C-Chaloalkoxy;'}{'sup': 6', '7', '7', '8', '3', '8', '3', '9', '6', '7', '7', '8', '3', '8', '3', '9, 'sub': 2', '2', '1', '4', '1', '4', '1', '4', '1', '4, 'or Rand R, Rand R, Rand R, or Rand Rtogether with the fragment of the pyridyl ring to which they are attached may form a partially or fully unsaturated 5- to 7-membered carbocyclic ring, and wherein the ring formed by Rand R, Rand R, Rand R, or Rand Ris optionally ...

Подробнее
25-04-2013 дата публикации

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

Номер: US20130102632A1
Принадлежит: Gilead Sciences, Inc.

The present invention relates to sodium channel inhibitors of Formula (I): 2. The compound of claim 1 , wherein Ris alkyl of 1-3 carbon atoms or phenyl optionally substituted by halo.3. The compound of claim 2 , wherein R claim 2 , Rand Rare independently chosen from hydrogen and halo.4. The compound of claim 3 , wherein Ris alkyl of 1-6 carbon atoms.5. The compound of claim 4 , wherein X is a covalent bond claim 4 , —C(O)O— claim 4 , or heteroaryl claim 4 , Y is methylene claim 4 , and Z is cycloalkyl or phenyl claim 4 , both of which are optionally substituted by halo or heteroaryl.6. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is 2-bromophenyl claim 5 , namely 2-bromobenzyl 2 claim 5 ,4-dimethylquinoline-3-carboxylate.7. The compound of claim 5 , wherein Ris methyl claim 5 , Ris phenyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is phenyl claim 5 , namely benzyl 2-methyl-4-phenylquinoline-3-carboxylate.8. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is 4-chlorophenyl claim 5 , namely 4-chlorobenzyl 2 claim 5 ,4-dimethylquinoline-3-carboxylate.9. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is a covalent bond claim 5 , Y is 1 claim 5 ,3 claim 5 ,4-oxadiazole claim 5 , and Z is (4-chlorophenyl)propan-2-yl) claim 5 , namely 2-(2-(4-chlorophenyl)propan-2-yl)-5-(2 claim 5 ,4-dimethylquinolin-3-yl)-1 claim 5 ,3 claim 5 ,4-oxadiazole.10. The compound of claim 5 , wherein Ris methyl claim 5 , Ris phenyl claim 5 , Rand Rare hydrogen claim 5 , Ris 6-chloro claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is cyclopropyl claim 5 , namely ...

Подробнее
25-04-2013 дата публикации

NOVEL CURING AGENTS

Номер: US20130102756A1
Автор: Cawse John
Принадлежит: Hexcel Composites Limited

A curable resin comprising a compound having the structure (I): wherein each carbon 2, together with either its carbon 1 or carbon 3, arc members of a fused cycloaliphatic ring, and when carbon 1 is a member of the ring so is N, and wherein each of the aliphatic or aromatic ring-member carbons may either be members of further fused cycloaliphatic rings or be bonded to a group selected from H or linear or branched Cto Calkyl. 2. A curable resin according to claim 1 , wherein any carbons forming part of any further fused cycloaliphatic rings are also bonded to either an H or linear or branched Cto Calkyl.3. A curable resin according to claim 1 , wherein each of the aliphatic or aromatic ring-member carbons claim 1 , which are not members of a fused cycloaliphatic ring claim 1 , are bonded to an H or linear or branched Cto Calkyl.4. A curable resin according to claim 1 , wherein the compound has a molecular weight of no greater than 600.5. A curable resin according to claim 1 , wherein the fused cycloaliphatic rings comprise five or six carbons.8. A curable resin according to claim 1 , wherein carbon 2 is a member of two fused cycloaliphatic rings claim 1 , one with carbon 1 and the other with carbon 3.9. A curable resin according to claim 1 , having a melting point of from 80° C. to 200° C.10. A curable resin according to claim 1 , wherein the resin is an epoxy or urethane.11. A curable resin according to claim 1 , comprising a fibre reinforcement.12. A curable resin according to claim 11 , which is a prepreg claim 11 ,13. A cured resin made by exposing a curable resin according to to elevated temperature.14. A cured resin according to claim 13 , which has a glass transition temperature of greater than 100° C.15. A cured resin according to which forms part of a structural member of an aerospace structure. The present invention relates to novel resin curing agents, particularly for epoxy and urethane resins.Curable resin systems are widely known and have a wide range ...

Подробнее
02-05-2013 дата публикации

Method of ameliorating oxidative stress and supplementing the diet

Номер: US20130108605A1

A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R 1 is an aromatic backbone and R 2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R 2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.

Подробнее
02-05-2013 дата публикации

ACTIVATORS OF HUMAN PYRUVATE KINASE

Номер: US20130109672A1

Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A, A, L, R, Rto R, Xto X, k, n, and m are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer. A-NR-L-A(I). 2. (canceled)3. The compound or salt of claim 1 , wherein the phenyl ring of the bicyclic ring of R′ is fused with an aryl claim 1 , a heteroaryl claim 1 , a cyclyl claim 1 , or a heterocyclyl claim 1 , each of which is optionally substituted with one or more substituents selected from the group consisting of aryl claim 1 , heteroaryl claim 1 , cyclyl claim 1 , alkyl claim 1 , alkoxyl claim 1 , halogen claim 1 , NH claim 1 , NH—(C-C)alkyl claim 1 , N—(C-C)alkyl-(C-C)alkyl claim 1 , (C-C)alkyl-OC— claim 1 , and heterocyclyl claim 1 , each of which other than halogen and NHis further optionally substituted with one or more substituents selected from the group consisting of NH claim 1 , OH claim 1 , NH—(C-C)alkyl and N—(C-C)alkyl-(C-C)alkyl.4. The compound or salt of claim 1 , wherein the cyclyl or heterocyclyl of R′ or R″ is a five-membered claim 1 , six-membered claim 1 , or seven-membered ring.5. The compound or salt of claim 1 , wherein the heterocyclyl contains one or two heteroatoms.6. The compound or salt of claim 1 , wherein R is methyl or H.8. The compound or salt of claim 7 , wherein one Ris at the ortho position relative to the carbon attached to the NR-L moiety.9. The compound or salt of claim 7 , wherein one Ris H claim 7 , F claim 7 , Cl claim 7 , Br claim 7 , methyl claim 7 , N(Me) claim 7 , NHMe claim 7 , 1-piperidinyl claim 7 , 2-(dimethylamino)ethyl)(methyl)amino claim 7 , pyrrolidin-1-yl claim 7 , 3-(dimethylamino)pyrrolidin-1-yl claim 7 , 2-hydroxy-2-methylpropylamino claim 7 , isopropylamino claim 7 , diethylamino claim 7 , 1-hydroxypropan-2-ylamino claim 7 , 2-hydroxyethylamino claim 7 , or phenyl.10. The compound or salt of claim 1 , wherein ...

Подробнее
02-05-2013 дата публикации

ANTIMICROBIAL AGENTS

Номер: US20130109713A1
Принадлежит:

The invention provides a compound of formula I:or a salt thereof, wherein R-Rand X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents. 2. The compound of wherein:{'sup': 1', 'y', 'y, 'sub': 1', '6, 'Ris Ror (C-C)alkyl that is substituted with one or more R;'}{'sup': 2', 'z', 'x, 'sub': 1', '6, 'Ris Ror (C-C)alkyl that is substituted with one or more R;'}{'sup': 4', '5', '6', '7', 'd', '4', '5', '6', '7', 'p', 'p', 'p', 'g', 'h', 'g', 'h', 'a', '4', '5', '6', '7', 'b, 'sub': 1', '6', '3', '6', '1', '6', '1', '6', '1', '6', '1', '6', '2', '3', '2', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'at least one of RRRand Ris aryl or heteroaryl wherein each aryl or heteroaryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) R; and the remainder of RRRand Rare each independently H, halo, cyano, nitro, hydroxy, carboxy, trifluoromethyl, trifluoromethoxy, (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkoxy, (C-C)alkoxycarbonyl, (C-C)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, (C-C)alkylthio, —S(O)R, —S(O)R, —S(O)R, —S(O)NRR, and —NRR; wherein any alkyl and any alkyl or alkanoyl portion of any aryl(C-C)alkyl, heteroaryl(C-C)alkyl, aryl(C-C)alkanoyl or heteroaryl(C-C)alkanoyl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) R; and wherein any aryl, heteroaryl, or any aryl or heteroaryl portion of any aryl(C-C)alkyl, heteroaryl(C-C)alkyl, aryl(C-C)alkanoyl or heteroaryl(C-C)alkanoyl of RRRand Ris optionally substituted with one or more (e.g. 1, 2, 3, or 4) R;'}{'sup': 8', 'p', 'p', 'p', 'g', 'h', 'g', 'h', '8', 'a', '8', 'b, 'sub': 1', '6', '3', '6', '1', '6', '1', '6', '1', '6', '1', '6', '2', '3', '2, 'Ris H, halo, cyano, nitro, hydroxy, carboxy, trifluoromethyl, trifluoromethoxy, (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkoxy, (C-C)alkoxycarbonyl, (C-C)alkanoyloxy, aryl, heteroaryl, aryloxy, ...

Подробнее
02-05-2013 дата публикации

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

Номер: US20130109717A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof. 170-. (canceled)71. A method for treating a CFTR mediated disease in a mammal comprising administering a solid form of a compound selected from Compound 1.2-methylbutyric acid , Compound 1.propylene glycol , Compound 1.PEG 400.KOAc , Compound 1.lactic acid , Compound 1.isobutyric acid , Compound 1.propionic acid , Compound 1.EtOH , Compound 1.2-propanol , Compound 1.besylate , and Compound 1.besylate.HO.72. The method of claim 71 , wherein said disease is selected from cystic fibrosis claim 71 , hereditary emphysema claim 71 , hereditary hemochromatosis claim 71 , coagulation-fibrinolysis deficiencies claim 71 , such as protein C deficiency claim 71 , Type 1 hereditary angioedema claim 71 , lipid processing deficiencies claim 71 , such as familial hypercholesterolemia claim 71 , Type 1 chylomicronemia claim 71 , abetalipoproteinemia claim 71 , lysosomal storage diseases claim 71 , such as I-cell disease/pseudo-Hurler claim 71 , mucopolysaccharidoses claim 71 , Sandhof/Tay-Sachs claim 71 , Crigler-Najjar type II claim 71 , polyendocrinopathy/hyperinsulemia claim 71 , Diabetes mellitus claim 71 , Laron dwarfism claim 71 , myleoperoxidase deficiency claim 71 , primary hypoparathyroidism claim 71 , melanoma claim 71 , glycanosis CDG type 1 claim 71 , hereditary emphysema claim 71 , congenital hyperthyroidism claim 71 , osteogenesis imperfecta claim 71 , hereditary hypofibrinogenemia claim 71 , ACT deficiency claim 71 , Diabetes insipidus (DI) claim 71 , neurophyseal DI claim 71 , neprogenic DI claim 71 , Charcot-Marie Tooth syndrome claim 71 , Perlizaeus-Merzbacher disease claim 71 , neurodegenerative diseases such as Alzheimer's disease claim 71 , Parkinson's disease claim 71 , amyotrophic lateral sclerosis claim 71 , progressive supranuclear plasy claim 71 , Pick's disease claim 71 , several polyglutamine ...

Подробнее
02-05-2013 дата публикации

METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES

Номер: US20130109860A1
Принадлежит: ACTIVE BIOTECH AB

A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191° C.; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture. 115-. (canceled)17. A method according to claim 16 , wherein the aliphatic solvent(s) have a boiling point in the range of 80-150° C.18. A method according to claim 16 , wherein the aliphatic solvent(s) have a boiling point in the range of 95-130° C.19. A method according to claim 16 , wherein the alcohol scavenging agent is selected from 3 A claim 16 , 4 A claim 16 , 5 A claim 16 , 13× molecular sieves or is a mixture of any of said molecular sieves.20. A method according to claim 16 , wherein the aliphatic solvent(s) is/are selected from C6-C10 branched or linear alkanes and cycloalkanes.21. A method according to claim 16 , wherein the aliphatic solvent(s) is/are selected from C7-C8 branched or linear alkanes and cycloalkanes.22. A method according to claim 21 , wherein the aliphatic solvent(s) is/are selected from n-heptane claim 21 , n-octane claim 21 , methylcyclohexane claim 21 , 2 claim 21 ,2 claim 21 ,4-trimethylpentane and cyclooctane.23. A method according to claim 22 , wherein the aliphatic solvent(s) is/are selected from n-heptane and n-octane.24. A method according to claim 16 , wherein R4 is selected from methyl claim 16 , ethyl claim 16 , n-propyl claim 16 , iso-propyl and n-butyl.25. A method according to claim 24 , wherein R4 is selected from methyl and ethyl.26. A method according to claim 16 , wherein R1 is ethyl claim 16 , R2 is ethyl claim 16 , R3 is H claim 16 , R4 is methyl or ethyl; the alcohol scavenging agent is a 3 A claim 16 , 4 A claim 16 , 5 A or 13× molecular sieve claim ...

Подробнее
09-05-2013 дата публикации

FLUORESCENT DYES

Номер: US20130115651A1
Принадлежит: ENZO BIOCHEM, INC.

The present invention provides dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes provided in this invention can comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been substituted with specific groups to provide beneficial properties. 130-. (canceled)34. A method of identifying a specific organelle or region in a cell of interest , the method comprising{'claim-ref': {'@idref': 'CLM-00037', 'claim 37'}, '(a) incubating the cell of interest with the compound of , and'}(b) identifying the location of the organelle or region in the cell of interest by identifying the compound that stains the organelle or region.37. A target molecule comprising the compound of .38. The target molecule of claim 37 , wherein the target molecule is a nucleoside claim 37 , a nucleotide claim 37 , an oligonucleotide claim 37 , a polynucleotide claim 37 , a peptide nucleic acid claim 37 , a protein claim 37 , an oligopeptide claim 37 , an enzyme claim 37 , an antibody claim 37 , a cytokine claim 37 , avidin claim 37 , streptavidin claim 37 , digoxigenin claim 37 , an oligosaccharide claim 37 , a polysaccharide claim 37 , a lipid claim 37 , a liposome claim 37 , a glycolipid claim 37 , or a dye.39. The target molecule of claim 37 , wherein the target molecule is a protein claim 37 , an oligopeptide claim 37 , a nucleotide claim 37 , an oligonucleotide claim 37 , or a polynucleotide.41. The compound of claim 40 , wherein said reactive group comprises a nucleophilic reactive group claim 40 , an electrophilic reactive group claim 40 , a terminal alkene claim 40 , a terminal alkyne claim 40 , a coordinate group or an alkylating agent.42. The ...

Подробнее
09-05-2013 дата публикации

QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS

Номер: US20130116206A1
Принадлежит: IMPERIAL INNOVATIONS LIMITED

There is provided compounds of formula (I), wherein R, R, X, X, and Xhave meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as positron emission tomography (PET) imaging agents, useful in the treatment of diseases in which inhibition of epidermal growth factor receptor tyrosine kinase activity or the inhibition of HER2 activity is desired and/or required, and useful in the treatment of cancer. 2. A compound as claimed in claim 1 , wherein Rrepresents Hetor a Calkyl group optionally substituted by one or more A groups.3. A compound as claimed in claim 1 , wherein A represents —N(R)R.5. A compound as claimed in claim 1 , wherein Rrepresents a C-alkoxy group optionally substituted by one or more halogen atoms claim 1 , or Het.7. A compound as claimed in claim 1 , wherein Xrepresents a halogen claim 1 , ORor SR.9. A compound as claimed in claim 1 , which is selected from the group:{(E)-3-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-ylcarbamoyl]-allyl}-prop-2-ynyl-carbamic acid tert-butyl ester;(E)-Pent-2-en-4-ynoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide;(E)-4-[(2-Fluoroethyl)methyl amino]-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide;(E)-4-[(4-Fluorobenzyl)methylamino]-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide;(E)-4-{[1-(2-Fluoro-ethyl)-1H-[1,2,3]triazol-4-ylmethyl]-amino}-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide hydrochloride;(E)-N-[4-(3-Chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl]-3-[1-(2-fluoro-ethyl)-1H-[1,2,3]triazol-4-yl]-acrylamide;(E)-4-Methylamino-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-fluoroethoxy)-quinolin-6-yl]-amide hydrochloride;(E)-4-Prop-2-ynylaminobut-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide hydrochloride;(E)-4-Methylamino- ...

Подробнее
09-05-2013 дата публикации

INHIBITORS OF HIF AND ANGIOGENESIS

Номер: US20130116275A1
Принадлежит:

Inhibitors of the Hypoxia Inducible Factor (HIF) and angiogenesis and their methods of use including the treatment of cancer, hypoxia related pathologies, disorders leading to ischemia, for example stroke and ischemic heart disease, and non-cancerous angiogenic diseases are provided. 2. The compound of claim 1 , wherein A is —CRR—.3. The compound of claim 1 , wherein X is N claim 1 , Y is CR claim 1 , and Z is CR.4. The compound of claim 1 , wherein Y is N claim 1 , X is CR claim 1 , and Z is CR.5. The compound of claim 1 , wherein Z is N claim 1 , X is CR claim 1 , and Y is CR.6. The compound of claim 1 , wherein Ris a cyclopropyl claim 1 , cyclobutyl or cyclopentyl.7. The compound of claim 1 , wherein Rand Rare alkyl.8. The compound of claim 1 , wherein Ris alkyl other than methyl.9. The compound of claim 1 , wherein is a double bond claim 1 , E is CR claim 1 , and A is —CR═CR—.10. The compound of claim 1 , wherein Ris 4-methoxyphenyl claim 1 , 3 claim 1 ,4-dimethoxyphenyl claim 1 , or 3 claim 1 ,5-dimethylphenyl.11. The compound of selected from the group:N-cyclopentyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide;N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-4-methoxy-N-phenylbenzenesulfonamide;N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3,5-dimethyl-N-phenylbenzenesulfonamide;N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-dimethoxy-N-phenylbenzenesulfonamide;N-cyclopentyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide;N-cyclobutyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide;N-butyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-dimethoxybenzenesulfonamide; andN-cyclopentyl-N-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-3,4-dimethoxybenzenesulfonamide or salts thereof.12. A pharmaceutical compositions comprising a compound as provided in or pharmaceutically acceptable salt and a pharmaceutically acceptable excipient.13. A method of treatment ...

Подробнее
09-05-2013 дата публикации

PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS

Номер: US20130116437A1
Принадлежит: Gilead Sciences, Inc.

The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties. 19-. (canceled)11. The method of wherein the compound of formula 3 is converted to the compound of formula 4 by treatment with a silane reducing agent in the presence of an acid.12. The method of wherein the silane reducing agent is triethylsilane and the acid is trifluoroacetic acid.19. The method of wherein the compound of formula 9 is converted to the compound of formula 10 by treatment with a base.2023-. (canceled) This application is a continuation of Ser. No. 12/892,682, filed on 28 Sep. 2010, which is a continuation of Ser. No. 11/853,606, filed on 11 Sep. 2007, now U.S. Pat. No. 7,825,252, granted on 2 Nov. 2010, and claims priority under 35 U.S.C. 119(e) from U.S. Provisional Patent Application No. 60/844,020 filed 12 Sep. 2006, and from U.S. Provisional Patent Application No. 60/905,365 filed 7 Mar. 2007.International Patent Application Publication Number WO 2004/046115 provides certain 4-oxoquinolone compounds that are useful as HIV integrase inhibitors. The compounds are reported to be useful as anti-HIV agents.International Patent Application Publication Number WO 2005/113508 provides certain specific crystalline forms of one of these 4-oxoquinolone compounds, 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinolone-3-carboxylic acid. The specific crystalline forms are reported to have superior physical and chemical stability compared to other physical forms of the compound.There is currently a need for improved methods for preparing the 4-oxoquinolone compounds reported in International Patent Application Publication Number WO 2004/046115 and in International Patent Application Publication Number WO 2005/113508. In particular, there is a need for new synthetic methods that are simpler or less expensive to carry out, that provide an ...

Подробнее
09-05-2013 дата публикации

IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND

Номер: US20130116438A1
Автор: Nara Hideki, Shimizu Hideo
Принадлежит: TAKASAGO INTERNATIONAL CORPORATION

An object of the present invention is to provide a novel iridium complex, and to provide a novel catalyst having excellent performances in terms of enantioselectivity, catalytic activity, and the like. Provided is an iridium complex of the following general formula (1): 111.-. (canceled)12. An iridium complex of the following general formula (1):{'br': None, 'sub': 2', 'm, 'IrHZ(PP)(Q)\u2003\u2003(1)'}wherein Z represents a halogen atom,PP represents a bisphosphine,Q represents an amine, andm represents 1 or 2.13. The iridium complex according to claim 12 , whereinPP in the general formula (1) is an optically active bisphosphine.14. The iridium complex according to claim 13 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'Q in the general formula (1) is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'}19. The production method according to claim 17 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'the amine is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'}21. An asymmetric hydrogenation catalyst comprising the iridium complex according to .23. The production method according to claim 18 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'the amine is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'} The present invention relates to an iridium complex and a method for producing an optically active compound.Synthetic methods based on catalytic ...

Подробнее
16-05-2013 дата публикации

INHIBITION OF BACTERIAL BIOFILMS WITH ARYL CARBAMATES

Номер: US20130123225A1
Принадлежит:

Disclosure is provided for carbamate compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same. 8. The compound of claim 1 , wherein n=1 to 5.9. The compound of claim 1 , wherein n=1 to 5 claim 1 , saturated.11. A composition comprising a carrier and an effective amount of the compound of .12. A composition comprising the compound of and a biocide.13. A composition comprising the compound of covalently coupled to a substrate.14. The composition of claim 13 , wherein said substrate comprises a polymeric material.15. The composition of claim 13 , wherein said substrate comprises a solid support.16. The composition of claim 13 , wherein said substrate is selected from the group consisting of a drainpipe claim 13 , glaze ceramic claim 13 , porcelain claim 13 , glass claim 13 , metal claim 13 , wood claim 13 , chrome claim 13 , plastic claim 13 , vinyl claim 13 , and laminate.17. The composition of claim 13 , wherein said substrate is selected from the group consisting of shower curtains or liners claim 13 , upholstery claim 13 , laundry claim 13 , and carpeting.18. A biofilm preventing claim 13 , removing or inhibiting coating composition claim 13 , comprising:(a) a film-forming resin;(b) a solvent that disperses said resin;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(c) an effective amount of the compound of , wherein said effective amount of said compound inhibits the growth of a biofilm thereon; and'}(d) optionally, at least one pigment.19. The coating composition of claim 18 , wherein said compound is covalently coupled to said resin.20. The coating composition of claim 18 , wherein said resin comprises a polymeric material.21. A substrate coated with the coating composition of .22. A method of controlling biofilm formation on a substrate comprising the step of contacting the compound of to said substrate in an amount effective to inhibit ...

Подробнее
16-05-2013 дата публикации

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Номер: US20130123258A1
Принадлежит:

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time. 2. The compound of having the Formula I.3. The compound of claim 2 , wherein the compound is selected from the group consisting of: 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15) claim 2 , 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16) claim 2 , 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (17) claim 2 , 3-ethyl-2 claim 2 ,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18) claim 2 , 3-ethyl-6-methoxy-2-methyl-7-(2-phenoxy-methoxy)-1H-quinolin-4-one (19) claim 2 , 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20) claim 2 , 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21) claim 2 , 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1 claim 2 ,4-dihydro-quinolin-7-yloxy)-propyl ester (22) claim 2 , 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23) claim 2 , 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24) claim 2 , 6-bromo-3-ethyl-2 ...

Подробнее
16-05-2013 дата публикации

UREA COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS

Номер: US20130123300A1
Принадлежит: CHINESE PLA GENERAL HOSPITAL

A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. 2. A compound of Formula I , or an isomer , pharmaceutically acceptable salt or solvate thereof , whereinA represents=O;X represents F, Cl, Br or I;{'sub': 1', '2, 'Rrepresents phenyl, phenyl-C1-C6 alkyl-, wherein said phenyl is unsubstituted or substituted with 1-4 (e.g., 1-2, 1, 2, 3 or 4) substituents independently selected from the group consisting of: halogens, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 halogenated alkyl, and wherein said alkyl, alkoxy and halogenated alkyl may be optionally substituted with hydroxyl, —O—(C1-C4)-alkyl, oxo, amino, —NH—(C1-C4)-alkyl, or —N—[(C1-C6)-alkyl], or said alkyl, alkoxy and halogenated alkyl can optionally intervened by —O—, —S—, —NH—, —COO—, or —CONH—;'}{'sub': '2', 'thienyl, thiazolyl, wherein said thienyl, thiazolyl is unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of: halogens, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 halogenated alkyl, and wherein said alkyl, alkoxy and halogenated alkyl may be optionally substituted with hydroxy, —O—(C1-C4)-alkyl, oxo, amino, —NH—(C1-C4)-alkyl, or —N—[(C1-C6)-alkyl], or said alkyl, alkoxy and halogenated alkyl can optionally be intervened by —O—, —S—, —NH—, —COO—;'}{'sub': 2', '3', '2', '3, 'Rand Rrepresent hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl ...

Подробнее
16-05-2013 дата публикации

METHOD OF PREVENTING OR TREATING VIRAL INFECTION

Номер: US20130123344A1

Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I): 2. The method of claim 1 , wherein for the compound of formula (I) claim 1 ,{'sup': 1', '2, 'sub': 1', '6, 'Rand Rare each independently H or C-Calkyl;'}{'sup': '3', 'claim-text': {'sub': '2', 'claim-text': [{'sub': 1', '6', '2', 'm', '6', '20', '2', 'n', '2', '2', 'q', '2, 'L is C-Calkylenyl, (CH)—(C-Caryl)-(CH), or (CHCHO)CH, wherein m and n are each independently 0 to 6 and q is 1 to 6, and'}, {'sup': '6', 'claim-text': [{'sup': 6', '7', '7', '7, 'wherein Ris NRRor OR, and'}, {'sup': '7', 'sub': '3', 'each Ris independently H or CH;'}], 'W is R,'}], 'wherein Y is linked to N and is CH, C═O, or NH,'}, 'Ris H or a group of the formula: —Y-L-W'}{'sup': 4', '5, 'sub': 1', '6, 'Rand Rare each independently H or C-Calkyl; and'}X is O.5. The method of claim 1 , wherein the compound is any one compound listed in Tables 2-4.6. The method of claim 1 , wherein the siRNA is any one of SEQ ID NOS: 1-4.7. The method of claim 1 , wherein the viral infection involves reactivation of a virus after latency in the host.8. The method of claim 1 , wherein the viral infection is due to a herpesvirus.9. The method of claim 1 , wherein the method further comprises administering to the host an inhibitor of the LSD 1 protein.10. The method of claim 9 , wherein the inhibitor of the LSD 1 protein is a monoamine oxidase inhibitor or an RNAi molecule.11. The method of claim 10 , wherein the monoamine oxidase inhibitor is pargyline or tranylcypromine.13. The method of claim 12 , wherein for the compound of formula (I) claim 12 ,{'sup': 1', '2, 'sub': 1', '6, 'Rand Rare each independently H or C-Calkyl;'}{'sup': '3', 'claim-text': {'sub': '2', 'claim-text': [{'sub': 1', '6', '2', 'm', '6', '20', '2', 'n', '2', '2', 'q', '2, 'L is C-Calkylenyl, (CH)—(C-Caryl)-(CH), or (CHCHO)CH, wherein m and n are each independently 0 to 6 and q is 1 to 6, and'}, {'sup': ...

Подробнее
23-05-2013 дата публикации

Analogues of cilostazol

Номер: US20130131021A1
Принадлежит: Concert Pharmaceuticals Inc

This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.

Подробнее
23-05-2013 дата публикации

NOVEL TRPV3 MODULATORS

Номер: US20130131036A1
Принадлежит: AbbVie Inc.

Disclosed herein are modulators of TRPV3 of formula (II): 2. The compound according to claim 1 , or a salt thereof claim 1 , wherein u is 0.3. The compound according to claim 2 , or a salt thereof claim 2 , wherein:{'sup': '1', 'Gis optionally substituted heteroaryl or optionally substituted cycloalkyl;'}{'sup': 2', '2d, 'Gis G; and'}{'sup': '2d', 'Gis optionally substituted aryl or optionally substituted heteroaryl.'}4. The compound according to claim 2 , or a salt thereof claim 2 , wherein:{'sup': '1', 'Gis optionally substituted pyridinyl, pyrimidinyl, thiazolyl, oxazolyl, or pyrazolyl;'}{'sup': 2', '2d, 'Gis G; and'}{'sup': '2d', 'Gis optionally substituted phenyl or optionally substituted pyridinyl.'}5. The compound according to claim 2 , or a salt thereof claim 2 , wherein:{'sup': 1', 'gc, 'sub': 1', '6', '1', '6', '2, 'Gis pyridinyl or pyrimidinyl; each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C-C-alkyl, C-C-haloalkyl, and N(R);'}{'sup': 'gc', 'sub': 1', '6, 'Ris hydrogen or C-C-alkyl;'}{'sup': 2', '2d, 'Gis G;'}{'sup': 2d', 'f, 'sub': 1', '6', '1', '6, 'Gis phenyl, pyridinyl, or pyrimidinyl; each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, —CN, C-C-alkyl, C-C-haloalkyl, and —OR; and'}{'sup': 'f', 'sub': 1', '6', '1', '6, 'Ris C-C-alkyl or C-C-haloalkyl.'}6. The compound according to claim 2 , or a salt thereof claim 2 , wherein:{'sup': 1', 'gc, 'sub': 1', '4', '1', '4', '2, 'Gis pyridinyl which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, C-C-alkyl, C-C-haloalkyl, and N(R);'}{'sup': 'gc', 'sub': 1', '4, 'Ris hydrogen or C-C-alkyl;'}{'sup': 2', '2d, 'Gis G;'}{'sup': 2d', 'f, 'sub': 1', '4', '1', '4, 'Gis phenyl or pyridinyl; each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group ...

Подробнее
23-05-2013 дата публикации

8-HYDROXY-QUINOLINE DERIVATIVES

Номер: US20130131096A1
Принадлежит:

The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula Rrepresents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein, the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; Rrepresents a hydrogen atom, lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted with one or more halogen atoms; Rrepresents a lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted in ortho, meta or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; Rrepresents a hydrogen atom, lower alkyl group or any acidic functional group; 2. Compounds of the general formula (I) according to wherein{'sub': 1', '1', '1', '1, 'Rrepresents a group substituted with an electron withdrawing group in para position, or a group substituted with an electron withdrawing group in meta position or an above group substituted with an electron donating group in ortho, meta or para position; or Rrepresents a double-substituted group with electron withdrawing groups in meta and para positions; or Rrepresents a double-substituted group with electron withdrawing groups in ortho and para positions; or Rrepresents an unsubstituted or substituted heterocyclic group;'}{'sub': 3', '1, 'Rrepresents and aromatic group substituted with an electron withdrawing group in para position; or Rrepresents a heteroaromatic or alicyclic group unsubstituted or substituted with alkyl group and/or electron withdrawing groups in ortho, meta or para position;'}{'sub': 2', '4, 'Rand Rrepresent hydrogen atom and'}n is 1.3. Compounds or the general formula (I) according to or claim 1 , wherein{'sub': '1', 'Rrepresents a phenyl group, ...

Подробнее
30-05-2013 дата публикации

HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Номер: US20130136794A1
Принадлежит: PEKING UNIVERSITY

Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. 2. The compound according to claim 1 , wherein the group A is substituted or unsubstituted heterocyclic group claim 1 , is the heterocyclic group being selected from pyridyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , furyl claim 1 , oxazolyl claim 1 , pyrazolyl claim 1 , thiazolyl or oxadiazolyl; preferably the group A is substituted or unsubstituted pyridyl claim 1 , or pyridyl fused with benzene or morpholine ring claim 1 , the fused benzene or morpholine ring being unsubstituted or substituted with methyl.3. The compounds according to claim 2 , wherein the Calkyl is methyl claim 2 , the Calkoxy is methoxy claim 2 , the Calkoxycarbonyl is methoxycarbonyl claim 2 , and/or the Calkylamido is pentylamido .4. The compound according to claim 3 , wherein the Rgroup is cyano.5. The compound according to claim 1 , wherein the compound is:3-(furan-2-ylmethyl)-4-hydroxy-1,3-thiazinane-2-thione (compound 1);2-(methoxycarbonyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 2);2-cyanoethyl(furan-2-ylmethyl)dithiocarbamate (compound 3);3-(furan-2-ylmethyl)-4-hydroxy-4,5-dimethyl-3,4-dihydro-2H-1,3-thiazine-2-thione (compound 4);2-sulfamoylethyl(furan-2-ylmethyl)dithiocarbamate (compound 5);2-boronoethyl(furan-2-ylmethyl)dithiocarbamate (compound 6);2-(methylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 7);2-(benzylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 8);4-hydroxy-3-(pyridin-3-ylmethyl)-1,3-thiazinane-2-thione ( ...

Подробнее
30-05-2013 дата публикации

HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME

Номер: US20130137720A1
Автор: Wang Xiang, Xu Wenqing

The present invention provides compounds, or derivatives or prodrugs thereof, that comprise a methyllysine mimic, and an α-ketoglutarate mimic that are attached through a linker and methods for using and producing the same. In some embodiments, compounds of the invention are of the formula: M-L-K, or a derivative or a prodrug thereof, wherein M is a methyllysine mimic, L is a linker, and K is an α-ketoglutarate mimic. 1. A compound of the formula: M-L-K , or a derivative or a prodrug thereof , wherein M is a methyllysine mimic , L is a linker , and K is an α-ketoglutarate mimic.3. The compound according to claim 2 , wherein Ris phenyl claim 2 , naphthyl claim 2 , benzyl claim 2 , or naphthylalkyl claim 2 , each of which is optionally substituted claim 2 , or fluorescein.4. The compound according to claim 2 , wherein X is NH.5. The compound according to claim 2 , wherein Y is O.6. The compound according to claim 2 , wherein Z is O.7. The compound according to claim 2 , wherein Ris C-Calkylene.8. The compound according to claim 2 , wherein Rand Rare methylene.9. The compound according to claim 2 , wherein Aris phenylene.10. The compound according to claim 2 , wherein Ris H or methyl.11. The compound according to claim 2 , wherein Ris alkyl or absent.13. The compound according to claim 12 , wherein Ris hydrogen or C-Calkyl.14. The compound according to claim 12 , wherein Xand Xare O.15. The compound according to claim 12 , wherein Yis —OR.16. The compound according to claim 12 , wherein Lis C-Calkylene or C-Calkenylene.17. A method for treating a clinic condition associated with activity of Jumonji C Domain-Containing Histone Demethylase comprising administering to the subject in need of such a treatment a therapeutically effective amount of a compound of .18. The method of claim 17 , wherein the clinical condition is a cancer or a mental retardation.19. A method for treating a clinic condition associated with overexpression of Jumonji C Domain-Containing Histone ...

Подробнее
30-05-2013 дата публикации

6-AMINOISOQUINOLINE COMPOUNDS

Номер: US20130137721A1
Принадлежит: AERIE PHARMACEUTICALS, INC.

6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided. 2. The compound of claim 1 , wherein Rand Rare hydrogen.3. The compound of claim 1 , wherein A is methylene or ethylene.4. The compound of claim 1 , wherein A is —O—CH— or —NH—CFl—.5. The compound of claim 1 , wherein Ris alkyl claim 1 , alkoxy claim 1 , cycloalkyl claim 1 , heterocycloalkyl claim 1 , aryl claim 1 , C-Calkyl aryl claim 1 , heteroaryl claim 1 , C-Calkyl heteroaryl claim 1 , carbonyl claim 1 , or carbonylamino6. The compound of claim 1 , wherein Ris aryl.7. The compound of claim 6 , wherein Ris substituted with heteroaryl claim 6 , acyl claim 6 , carboxyl claim 6 , carbonylamino claim 6 , nitro claim 6 , amino claim 6 , cyano claim 6 , halogen claim 6 , alkoxy claim 6 , or hydroxyl.8. The compound of claim 6 , wherein Ris phenyl.10. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) the compound according to ; and'}b) a carrier.11. The composition of claim 10 , wherein the carrier is selected from the group consisting of systemic and topical carriers.12. The composition of claim 11 , wherein the composition comprises about 0.001% to 10% of the 6-aminoisoquinoline derivative and 90 to 99.999% of the systemic carrier.13. A method for influencing the action of a kinase in a cell claim 11 , a tissue claim 11 , or a living mammal comprising administering to or contacting with the cell claim 11 , tissue claim 11 , or mammal at least one compound according to claim 11 , or increasing the effectiveness of another therapeutic agent in a cell claim 11 , tissue or living mammal comprising administering to ...

Подробнее
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
06-06-2013 дата публикации

Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Номер: US20130143881A1
Принадлежит: Exelixis Inc

This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient.

Подробнее
06-06-2013 дата публикации

(2e)-3-phenyl-n-[2,2,2-trifluoro-1-[[8-quinolineamino)thiomethyl]amino]ethyl]-2-acrylamide and pharmaceutical uses thereof

Номер: US20130143917A1
Принадлежит: CHINESE PLA GENERAL HOSPITAL

The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis

Подробнее
06-06-2013 дата публикации

Crystalline Pharmaceutical and Methods of Preparation and Use Thereof

Номер: US20130144063A1
Принадлежит: SARcode Bioscience Inc.

Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. 164-. (canceled)66. The method of claim 65 , wherein the palladium catalyst is 10% palladium on carbon.67. The method of claim 65 , wherein the proton source is formic acid. This application is a continuation of U.S. application Ser. No. 13/289,172 filed Nov. 4, 2011, which is a continuation of U.S. application Ser. No. 12/386,361 filed on Apr. 15, 2009, issued as U.S. Pat. No. 8,080,562 on Dec. 20, 2011, which claims the benefit of U.S. Provisional Application No. 61/045,142, filed Apr. 15, 2008, which applications are incorporated herein by reference.Cross reference is made to co-pending applications U.S. application Ser. No. 12/288,330, filed on Oct. 17, 2008; U.S. Ser. No. 12/386,359, filed on Apr. 15, 2009; U.S. Ser. No. 12/386,363, filed on Apr. 15, 2009; and U.S. Ser. No. 12/386,347, filed on Apr. 15, 2009, which are hereby incorporated by reference in their entirety.The compound of Formula I:has been found to be an effective inhibitor of Lymphocyte Function-Associated Antigen-1 (LFA-1) interactions with the family of Intercellular Adhesion Molecules (ICAM), and has desirable pharmacokinetic properties, including rapid systemic clearance. Improved forms, including crystalline forms, and their uses in treatment of disorders mediated by the interaction of LFA-1 and ICAM are described herein. Novel polymorphs of the compound of Formula I which may afford improved purity, stability, bioavailability and other like characteristics for use in pharmaceutical formulations and methods of use thereof are useful in treating disease.In a first aspect the invention provides a composition comprising a compound of Formula I:In some embodiments of the composition of a compound of Formula I, the ...

Подробнее
13-06-2013 дата публикации

THERAMUTEIN MODULATORS

Номер: US20130150358A1
Автор: Housey Gerard M.
Принадлежит: HMI MEDICAL INNOVATIONS, LLC.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein. 2. The method of wherein Xis N.3. The method of wherein Xis N.5. The method of wherein Xis N.6. The method of wherein Xis N.8. The method of wherein Xis N.9. The method of wherein Xis N.11. The method of wherein Xis N.12. The method of wherein Xis N.14. The method of wherein Xis N.15. The method of wherein Xis N.18. The method of wherein Xis N.19. The compound of wherein Xis N.21. The method of wherein Xis N.22. The method of wherein Xis N.24. The method of wherein Xis N.25. The method of wherein Xis N.27. The method of wherein Xis N.28. The method of wherein Xis N.30. The method of wherein Xis N.31. The method of wherein Xis N.33. The method of wherein Xis N.34. The method of wherein Xis N.36. The compound of wherein Xis N.37. The compound of wherein Xis N.52. A method for determining whether a substance is an inhibitor or an activator of a theramutein which is capable of eliciting a detectable phenoresponse claim 36 , which comprises:a) incubating a first cell which expresses the theramutein at a substantially constant level with the substance;b) incubating a second cell which expresses a corresponding prototheramutein at a substantially constant level with a known inhibitor or activator of the prototheramutein;c) comparing a phenoresponse of the second cell to the known inhibitor or activator of the prototheramutein to the phenoresponse of the first cell to the substance; andd) determining that the phenoresponse of the first cell is inhibited or activated to at least the same ...

Подробнее
13-06-2013 дата публикации

PYRAZOLOQUINOLINES

Номер: US20130150359A1

The invention relates to compounds of the formulae (I), (II) and (III), and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formula (II) or (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of its salts 7. A compound according to claim 6 , in whichR1, R2, independently of one another, denote A or -Alk-Ar,R10 denotes Hal,Alk denotes alkylene having 1-3 C atoms, in which 1-2 H atoms are optionally replaced by Hal,R4 denote Y,Y denotes H or A,A denotes unbranched or branched alkyl having 1-4 C atoms, in which, independently of one another, 1-3 H atoms are optionally replaced by Hal,Ar denotes phenyl which is unsubstituted or monosubstituted by Hal, andHal denotes F, Cl, Br or I,or a physiologically acceptable salt or tautomer thereof.11. A method for inhibiting a serine/threonine protein kinase claim 1 , a PIKK claim 1 , or DNA-PK claim 1 , comprising bringing together an effective amount of a compound of with said serine/threonine protein kinase claim 1 , a PIKK claim 1 , or DNA-PK.12. A method for sensitizing cancer cells to anticancer agents and/or ionising radiation claim 1 , comprising bringing together an effective amount of a compound of with said cancer cells with the proviso that the sensitisation does not take place in vivo on the human body.13. A pharmaceutical composition comprising a ...

Подробнее
13-06-2013 дата публикации

Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use

Номер: US20130150368A1
Принадлежит: Cytokinetics Inc

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, Z 1 , Z 2 , Z 3 , Z 4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Подробнее
13-06-2013 дата публикации

IMINOPROPENE COMPOUND AND USE THEREOF

Номер: US20130150392A1
Принадлежит: Sumitomo Chemical Company, Limited

The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition. 2. The compound according to claim 1 , wherein{'sup': 4', '5, 'sub': '2', 'X is SXor S(O)X'}{'sup': 4', '5', '21', 'A2', '21', 'A2, 'Xand Xare each independently a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or C(=Q)X(wherein, Qis an oxygen atom, and Xis a lower alkyl group optionally substituted), group optionally substituted or a heterocyclic group optionally'}{'sup': 1', '1', 'I1, 'sub': '2', 'Y is OY(wherein, Yis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or N═C(Y),'}{'sup': B', 'B', 'F', 'F', 'G', 'H', 'G', 'H, 'sub': '2', 'Z is a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted, C(═O)OZ(wherein, Zis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower ...

Подробнее
20-06-2013 дата публикации

Compounds for stem cell differentiation

Номер: US20130157947A1
Принадлежит: Individual

Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 6 , R 6′ , R 7 , R 7′ are as described herein.

Подробнее
20-06-2013 дата публикации

TRPV1 Antagonists

Номер: US20130158067A1
Принадлежит: AbbVie Inc.

Disclosed herein are compounds of formula (I): 2. The compound or salt according to claim 1 , wherein A is CH.3. The compound or salt according to claim 1 , wherein Xis O or N(R) claim 1 , and n is 2.4. The compound or salt according to claim 1 , wherein Xis O claim 1 , and n is 2.5. The compound or salt according to claim 1 , wherein Xis CH claim 1 , and n is 1.6. The compound or salt according to claim 1 , wherein L is CH.7. The compound or salt according to claim 1 , wherein L is a bond.8. The compound or salt according to claim 1 , wherein:A is CH;{'sup': 1', 'w, 'Xis O or N(R); and'}n is 2.9. The compound or salt according to claim 8 , wherein L is a bond.10. The compound or salt according to claim 8 , wherein L is CH.11. The compound or salt according to claim 10 , wherein Xis O.12. The compound or salt according to claim 1 , wherein:A is CH;{'sup': '1', 'sub': '2', 'Xis CH;'}n is 1; andLisa bond.14. The compound or salt according to claim 13 , wherein:A is CH;{'sup': 1', 'w, 'Xis O or N(R);'}n is 2; andL is a bond.15. The compound or salt according to claim 13 , wherein:A is CH;{'sup': '1', 'Xis O;'}n is 2; and{'sub': '2', 'L is CH.'}16. The compound or salt according to claim 13 , wherein:A is CH;{'sup': '1', 'sub': '2', 'Xis CH;'}n is 1; andL is a bond.18. The compound or salt according to claim 17 , wherein:A is CH;{'sup': '1', 'Xis O;'}n is 2; andL is a bond.19. The compound or salt according to claim 1 , wherein the compound is selected from the group consisting of:1-[(4R)-6,8-difluoro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea;1-[(4R)-8-chloro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea;1-[(4R)-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea;1-[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea;1-[(4R)-7-fluoro-2,2- ...

Подробнее
27-06-2013 дата публикации

Process for making sterile aripiprazole of desired mean particle size

Номер: US20130161848A1
Принадлежит: Bristol Myers Squibb Co

A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks.

Подробнее
27-06-2013 дата публикации

Quinoline or quinazoline derivatives with apoptosis inducing activity on cells

Номер: US20130165386A1
Принадлежит: HANMI SCIENCE CO LTD

Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Подробнее
27-06-2013 дата публикации

JAK1 Inhibitors

Номер: US20130165440A1
Принадлежит: Exelixis, Inc.

JAK1 inhibitors of structural formula (I), wherein Ar, Ar, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases. 2. The compound according to wherein:{'sup': 1', '1', '2, 'Aris phenyl optionally substituted with 1-2 Rgroups, or heteroaryl optionally substituted with 1-2 Rgroups;'}{'sup': 2', '5, 'Aris phenyl optionally substituted with 1-3 Rgroups;'}{'sup': 1', '3', '3', '4', '3', '4', '3, 'sub': '2', 'each Ris independently —C(O)OR, —C(O)R, —C(O)N(H)alkylR, —N(H)C(O)alkyl, —C(O)N(R)(R), or —SOR;'}{'sup': 2', '3', '4', '3, 'each Ris independently —N(R)(R), alkyl, or —C(O)OR;'}{'sup': '3', 'Ris H or alkyl;'}{'sup': '4', 'Ris H or alkyl optionally substituted with heterocyclyl;'}{'sup': 5', '3', '6', '6', '3', '6', '3, 'each Ris independently halo, —CN, —C(O)OR, R, —OR, —N(R)R, alkyl optionally substituted with 1-3 halo, alkoxy optionally substituted with 1-3 halo, or heterocyclyl optionally substituted with R;'}{'sup': 6', '3', '7, 'Ris alkyl optionally substituted with —NRR;'}{'sup': '7', 'Ris H or alkyl;'}Q is C(H) or N;W is C(H) or N;X is C(H) or N;Y is C(H) or N; andZ is C(H) or N.4. The compound according to claim 3 , wherein:{'sup': 1', '1', '2, 'Aris phenyl optionally substituted with 1-2 Rgroups or heteroaryl optionally substituted with 1-2 Rgroups, wherein the heteroaryl is 1H-indazolyl, pyrazolyl, benzotriazolyl, or benzofuranyl, isoindolyl;'}{'sup': 5', '3', '6', '6', '3', '6', '3, 'sub': 1', '3, 'each Ris independently halo, —CN, —C(O)OR, R, —OR, —N(R)R, (C-C)alkyl optionally substituted with 1-3 halo, alkoxy optionally substituted with 1-3 halo, or heterocyclyl optionally substituted with R; and'}{'sup': '7', 'sub': 1', '3, 'Ris H or (C-C)alkyl.'}12. A composition comprising a compound according to and ...

Подробнее
27-06-2013 дата публикации

Modulators of ATP-Binding Cassette Transporters

Номер: US20130165442A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. 2. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier or adjuvant.3. The pharmaceutical composition according to claim 2 , further comprising an additional agent selected from a mucolytic agent claim 2 , a bronchodialator claim 2 , an antibiotic claim 2 , an anti-infective agent claim 2 , an anti-inflammatory agent claim 2 , a CFTR modulator claim 2 , or a nutritional agent.4. The pharmaceutical composition according to claim 2 , wherein said additional agent is a CFTR modulator other than a compound according to .5. A method of treating or lessening the severity of a disease in a patient claim 1 , wherein said disease is selected from cystic fibrosis claim 1 , asthma claim 1 , smoke induced COPD claim 1 , chronic bronchitis claim 1 , rhinosinusitis claim 1 , constipation claim 1 , pancreatitis claim 1 , pancreatic insufficiency claim 1 , male infertility caused by congenital bilateral absence of the vas deferens (CBAVD) claim 1 , mild pulmonary disease claim 1 , idiopathic pancreatitis claim 1 , allergic bronchopulmonary aspergillosis (ABPA) claim 1 , liver disease claim 1 , hereditary emphysema claim 1 , hereditary hemochromatosis claim 1 , coagulation-fibrinolysis deficiencies claim 1 , such as protein C deficiency claim 1 , Type 1 hereditary angioedema claim 1 , lipid processing deficiencies claim 1 , such as familial hypercholesterolemia claim 1 , Type 1 chylomicronemia claim 1 , abetalipoproteinemia claim 1 , lysosomal storage diseases claim 1 , such as I-cell disease/pseudo-Hurler claim 1 , mucopolysaccharidoses claim 1 , Sandhof/Tay-Sachs claim 1 , Crigler-Najjar type II claim ...

Подробнее
27-06-2013 дата публикации

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

Номер: US20130165479A1
Принадлежит: ABBVIE, INC.

The present application is directed to compounds that are TRPV1 antagonictc and have formula (I) 2. The compound according to wherein{'sub': 1', 'b, 'Yis —N(R)—;'}{'sub': '2', 'Yis O; and'}{'sub': 3', 'c, 'Yis —N(R)—.'}3. The compound according to claim 2 , wherein Lis cycloalkyl wherein the cycloalkyl is cyclopentyl or cyclohexyl.4. The compound of claim 3 , wherein Aris phenyl.5. The compound according to claim 4 , wherein the phenyl is unsubstituted or substituted with 1 claim 4 , 2 claim 4 , 3 claim 4 , 4 claim 4 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 4 , alkyl claim 4 , arylalkyl claim 4 , halogen claim 4 , haloalkyl claim 4 , or RRN— wherein Rand Rare each independently hydrogen claim 4 , alkyl claim 4 , or haloalkyl.6. The compound according to claim 5 , wherein{'sub': '1', 'Ris hydroxy; and'}{'sub': 2', '3', '4', '5, 'R, R, R, and Rare hydrogen.'}7. The compound according to claim 2 , wherein Lis a bond.8. The compound according to claim 7 , wherein Aris a monocyclic heterocycle fused to a phenyl.9. The compound of claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen, and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-3-yl.'}10. The compound according to wherein Aris optionally substituted with 1 claim 9 , 2 claim 9 , 3 claim 9 , 4 claim 9 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 9 , alkyl claim 9 , arylalkyl claim 9 , halogen claim 9 , haloalkyl claim 9 , or RRN— wherein Rand Rare each independently hydrogen claim 9 , alkyl claim 9 , or haloalkyl.11. The compound according to claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen; and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-4-yl.'}12. The compound according to wherein Aris optionally substituted with 1 claim 11 , 2 claim 11 , 3 claim 11 , 4 claim 11 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 11 , alkyl claim 11 , arylalkyl claim 11 , halogen claim 11 , ...

Подробнее
04-07-2013 дата публикации

TRPV1 ANTAGONISTS

Номер: US20130172334A1
Принадлежит: AbbVie Inc.

Disclosed herein are compounds of formula (I): 2. The compound or salt according to claim 1 , wherein A is CH claim 1 , Z is O claim 1 , and L is a bond.3. The compound or salt according to claim 1 , wherein A is CH claim 1 , Z is S claim 1 , and L is a bond.4. The compound or salt according to claim 1 , wherein A is N claim 1 , Z is O claim 1 , and L is a bond.5. The compound or salt according to claim 1 , wherein A is CH claim 1 , Z is O claim 1 , and L is CH.6. The compound or salt according to claim 1 , wherein Xis O and n is 2.7. The compound or salt according to claim 1 , wherein Xis CHand n is 1.8. The compound or salt according to claim 1 , wherein:G is formula (i);{'sup': '1', 'Xis O; and'}n is 2.9. The compound or salt according to claim 1 , wherein:G is formula (ii);{'sup': '1', 'Xis O; and'}n is 2.10. The compound or salt according to claim 1 , wherein:G is formula (iii);{'sup': '1', 'Xis O; and'}n is 2.11. The compound or salt according to claim 1 , wherein:G is formula (i);{'sup': '1', 'sub': '2', 'Xis CH; and'}n is 1.12. The compound or salt according to claim 1 , wherein:G is formula (ii);{'sup': '1', 'sub': '2', 'Xis CH; and'}n is 1.13. The compound or salt according to claim 1 , wherein:G is formula (iii);{'sup': '1', 'sub': '2', 'Xis CH; and'}n is 1.14. The compound or salt according to claim 6 , wherein A is CH.15. The compound or salt according to claim 6 , wherein A is N.16. The compound or salt according to claim 6 , wherein A is CH and Z is O.17. The compound or salt according to claim 6 , wherein A is N and Z is O.18. The compound or salt according to claim 6 , wherein A is CH claim 6 , Z is O claim 6 , and L is a bond.19. The compound or salt according to claim 6 , wherein A is N claim 6 , Z is O claim 6 , and L is a bond.20. The compound or salt according to claim 6 , wherein A is CH claim 6 , Z is O claim 6 , and L is CH.21. The compound or salt according to claim 6 , wherein A is CH claim 6 , Z is S claim 6 , and L is a bond.23. The ...

Подробнее
04-07-2013 дата публикации

Imidazo[4,5-c]quinolines as DNA-PK inhibitors

Номер: US20130172337A1

The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I). 7. Intermediate compounds according to in whichR1 denotes A,{'sub': 2', 'p', '2', 's, 'R2 denotes A or —(CH)—(CH)—Ar,'}R3 denotes CN,R5 denotes Hal,{'sub': '2', 'R8 denotes NH,'}A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,Hal denotes F, Cl, Br or I, andm, p, s, independently of one another, denote 0, 1 or 2,and/or salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.10. A method for the inhibition of serine/threonine protein kinases in vitro comprising introducing a compound according to and/or physiologically acceptable salts claim 1 , tautomers and/or stereoisomers thereof claim 1 , including mixtures thereof in all ratios to a sample containing serine/threonine protein kinases.11. A method for sensitizing cancer cells to an anticancer agent and/or ionizing radiation comprising introducing a compound according to and/or physiologically acceptable salts claim 1 , tautomers and/or stereoisomers thereof claim 1 , including mixtures thereof in all ratios claim 1 , to cancer ...

Подробнее
04-07-2013 дата публикации

4-oxoquinoline compound and use thereof as hiv integrase inhibitor

Номер: US20130172344A1
Принадлежит: Japan Tobacco Inc

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Подробнее
04-07-2013 дата публикации

1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES

Номер: US20130172345A1
Принадлежит: KOWA COMPANY, LTD.

Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); 1. A tetrahydroquinoline compound , a salt of the compound , a solvate of the compound , or a solvate of the salt , wherein the tetrahydroquinoline compound is selected from the group consisting of the following compounds:1-acetyl-8-fluoro-4-[(2-fluorophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (4)];1-cyclohexanecarbonyl-6-fluoro-4-[(4-fluorophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (6)];1-acetyl-7-cyano-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (7)];1-acetyl-6-cyano-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (14)];1-acetyl-4-[(4-isopropoxyphenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (18)];1-acetyl-2-methyl-4-[(4-morpholinophenyl)amino]-1,2,3,4-tetrahydroquinoline [Compound (19)];1-acetyl-4-[(4-N,N-dimethylaminophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (20)];1-acetyl-7-bromo-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (23)];1-acetyl-4-[(4-hydroxyphenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (24)]; 1-acetyl-2-methyl-4-[(1,1′-biphenyl-4-yl)amino]-1,2,3,4-tetrahydroquinoline [Compound (25)];1-acetyl-2-methyl-4-phenoxy-1,2,3,4-tetrahydroquinoline [Compound (26)];1-acetyl-4-(4-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (27)];1-acetyl-4-(3-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (28)];1-acetyl-4-(2-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (29)];1-acetyl-4-(2,4-difluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (30)];1-acetyl-4-(3,4-difluorophenoxy)- ...

Подробнее
04-07-2013 дата публикации

USE OF KYNURENIC ACID AMIDE DERIVATIVES FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Номер: US20130172346A1
Принадлежит:

The invention is directed to kynurenic acid analogues and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds for treating the symptoms of Huntington's disease and preventing the development of the symptoms. 2. The compound as claimed in selected from the group consisting of:2-(2-N,N-dimethylaminoethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(3-N,N-dimethylaminopropylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N,N-diethylaminoethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N-morpholino-ethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N-piperidylethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N-pyrrolidyl-ethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride and2-[2-(2-N-methylpiperidyl)-methylamino-1-carbonyl]-1H-quinolin-4-one hydrochloride,for use in the treatment of the symptoms of Huntington's disease and for preventing the development of said symptoms.3. 2-(2-N claim 1 ,N-dimethylaminoethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride as claimed in for use in the treatment of the symptoms of Huntington's disease and for preventing the development of said symptoms.4. Pharmaceutical composition comprising as active ingredient a pharmaceutically efficient amount of KYNA amide derivatives of the general formula (1) or pharmaceutically acceptable acid addition salts thereof claim 1 , wherein the substituents are defined in claim 1 , together with pharmaceutically acceptable carriers and excipients claim 1 , for use in the treatment of Huntington's disease.5. The pharmaceutical composition as claimed in claim 4 , comprising as active ingredient any of the following compounds or a combination thereof:2-(2-N,N-dimethylaminoethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(3-N,N-dimethylaminopropylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N,N-diethylaminoethylamino-1-carbonyl)-1H-quinolin-4-one hydrochloride,2-(2-N-morpholino-ethylamino-1- ...

Подробнее
04-07-2013 дата публикации

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Номер: US20130172363A1
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. 1. A compound having the name (S)—N-hydroxy-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]-2-[4-(propane-2-sulfonyl)piperazin-1-yl]propionamide.2. A composition comprising the compound as claimed in claim 1 , and an acceptable carrier.3. A pharmaceutical composition comprising the compound claim 1 , as claimed in and a pharmaceutically acceptable carrier.5. The compound as claimed in claim 4 , in which{'sub': '4', 'Ris an alkyl radical containing 1 to 4 carbon atoms; and'}{'sub': '3', 'Ris a polycyclic aromatic heterocylic radical containing the heteroatom N;'}and salts thereof, and enantiomers thereof.6. The compound as claimed in claim 4 , wherein the compound is (S)—N-hydroxy-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]-2-[4-(propane-2-sulfonyl)piperazin-1-yl]propionamide claim 4 , and salts thereof claim 4 , and enantiomers thereof.7. A composition comprising the compound as claimed in claim 4 , or a salt thereof claim 4 , or an enantiomer thereof claim 4 , and an acceptable carrier.8. A pharmaceutical composition comprising the compound as claimed in claim 4 , a salt thereof claim 4 , or an enantiomer thereof claim 4 , and a pharmaceutically acceptable carrier.9. A method of treating an inflammatory skin disease claim 3 , wherein the method comprises administering the pharmaceutical composition as claimed in claim 3 , to a subject in need thereof.10. The method of claim 9 , wherein the inflammatory skin disease is psoriasis or atopic dermatitis.11. A method of treating an inflammatory skin disease claim 8 , wherein the method comprises administering the pharmaceutical composition as claimed in claim 8 , to a subject in need thereof.12. The method of claim 11 , wherein the inflammatory skin ...

Подробнее
11-07-2013 дата публикации

PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS

Номер: US20130178494A1
Принадлежит: Academia Sinica

The present disclosure relates to new DNA-directed alkylating agents and water-soluble N-mustard agents with improved chemical stability and anti-tumor therapeutic efficacy. 3. The compound of claim 2 , wherein X and Y are the same.4. The compound of claim 3 , wherein X and Y are Cl.5. The compound of claim 2 , wherein Z is —NH.6. The compound of claim 2 , wherein Z′ is —NH.7. The compound of claim 2 , wherein Z′ is —NHNH.8. The compound of claim 1 , wherein each of R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Ris independently hydrogen claim 1 , halogen claim 1 , alkyl claim 1 , alkenyl claim 1 , alkynyl claim 1 , heterocyclyl claim 1 , aryl claim 1 , —OR claim 1 , —OC(O)R claim 1 , —SR claim 1 , —N(R) claim 1 , —N(R)C(O)R claim 1 , —C(O)N(R) claim 1 , —CN claim 1 , —NO claim 1 , —C(O)R claim 1 , —C(O)OR claim 1 , —S(O)R claim 1 , —SOR claim 1 , —SON(R) claim 1 , or —NHSOR.9. The compound of claim 8 , wherein each of R claim 8 , R claim 8 , R claim 8 , R claim 8 , Rand Ris selected from the group consisting of —H claim 8 , —OH claim 8 , —Cl claim 8 , —Br claim 8 , —F claim 8 , methyl claim 8 , ethyl claim 8 , methoxy claim 8 , ethoxy claim 8 , —C≡C-aryl claim 8 , phenyl claim 8 , naphthyl claim 8 , —NO claim 8 , —NH—Calkyl claim 8 , —C(O)CH claim 8 , —COH claim 8 , —COEt claim 8 , —CONH-aryl claim 8 , —CN claim 8 , N-morpholinyl claim 8 , —SO-alkyl claim 8 , and —SO-aryl.10. The compound of claim 2 , wherein Rand Rare taken together with their intervening atoms to form a heterocycle.11. The compound of claim 1 , wherein Rand Rare taken together with their intervening atoms to form a 6-membered aromatic ring claim 1 , wherein the ring is unsubstituted or substituted by one or more R′ group; and R′ is hydrogen claim 1 , halogen claim 1 , C-Calkyl claim 1 , alkenyl claim 1 , alkynyl claim 1 , heterocyclyl claim 1 , aryl claim 1 , —OR claim 1 , —OC(O)R claim 1 , —SR claim 1 , —N(R) claim 1 , —N(R)C(O)R claim 1 , —C(O)N(R) claim 1 , —CN claim 1 , —NO claim 1 , — ...

Подробнее
11-07-2013 дата публикации

Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors

Номер: US20130178499A1
Принадлежит: N30 PHARMACEUTICALS, INC.

The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. 3. The compound of wherein m is selected from the group consisting of 0 and 1; Rand Rare independently selected from the group consisting of hydrogen claim 1 , chloro claim 1 , fluoro claim 1 , methyl claim 1 , trifluoromethyl claim 1 , cyano claim 1 , methoxy claim 1 , and N(CH); n is selected from the group consisting of 0 and 1; and Ris independently selected from the group consisting of fluoro claim 1 , chloro claim 1 , bromo claim 1 , methyl claim 1 , trifluoromethyl claim 1 , cyano claim 1 , hydroxy claim 1 , methoxy claim 1 , and N(CH).5. The compound of wherein A is COOH.6. The compound of selected from the group consisting of4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid;2-(4-(1H-tetrazol-5-yl)phenyl)-3-methylquinolin-6-ol;4-(6-hydroxyquinolin-2-yl)benzoic acid;2-(4-(1H-tetrazol-5-yl)phenyl)quinolin-6-ol;1-(6-hydroxyquinolin-2-yl)piperidine-4-carboxylic acid;(1r,4r)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic acid;(1s,4s)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic acid;3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid;2-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid;2-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid;2-(4-(2H-tetrazol-5-yl)phenyl)-4-chloroquinolin-6-ol;3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(2H)-one;3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid;4-(6-hydroxyquinolin-2-yl)-3-methoxybenzoic acid;5-(6-hydroxyquinolin-2-yl)thiophene-2-carboxylic acid;4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylic acid;4-(3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;4-(3-chloro-6-hydroxyquinolin-2-yl)benzoic acid;3-(2-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one;3-(3-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one;4-(4-chloro- ...

Подробнее
18-07-2013 дата публикации

Adamantyl diamide derivatives and uses of same

Номер: US20130184277A1
Принадлежит: H Lundbeck AS

The present invention provides adamantyl diamide derivatives of formula (I): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

Подробнее
18-07-2013 дата публикации

NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME

Номер: US20130184464A1
Принадлежит: Dong Kook Pharm. Co., Ltd.

Disclosed are a novel montelukast 4-halobenzylamine salt, and a method for preparing a montelukast sodium salt by using the same. In the disclosed method, a montelukast 4-halobenzylamine salt represented by Formula 2 or a montelukast sodium salt represented by Formula 1 is prepared by obtaining a compound represented by Formula 3 from a compound represented by Formula 5, in the same reactor, without an additional obtaining process. 4. The method as claimed in claim 3 , wherein step a) is to obtain the compound represented by Formula 3 by reacting the compound represented by Formula 5 with methanesulfonyl chloride claim 3 , then with the compound represented by Formula 4 claim 3 , followed by the base treatment claim 3 , without an additional obtaining process.5. The method as claimed in claim 3 , wherein in step a) claim 3 , the reaction with the compound represented by Formula 4 is carried out in at least one base selected from the group consisting of cesium carbonate claim 3 , lithium hydroxide claim 3 , sodium hydroxide claim 3 , potassium hydroxide claim 3 , potassium carbonate claim 3 , and sodium carbonate.6. The method as claimed in claim 3 , wherein in step a) claim 3 , the reaction with the compound represented by Formula 4 is carried out in cesium carbonate.7. The method as claimed in any one of to claim 3 , wherein the step of reacting the compound represented by Formula 3 with the 4-halobenzylamine is carried out in at least one solvent selected from the group consisting of ethanol claim 3 , isopropyl alcohol claim 3 , acetone claim 3 , acetonitrile claim 3 , ethyl acetate claim 3 , tetrahydrofuran claim 3 , methylene chloride claim 3 , chloroform claim 3 , toluene claim 3 , xylene claim 3 , hexane claim 3 , cyclohexane and heptane.10. The method as claimed in claim 9 , wherein step a) is to obtain the compound represented by Formula 3 by reacting the compound represented by Formula 5 with methanesulfonyl chloride claim 9 , then with the compound ...

Подробнее
25-07-2013 дата публикации

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Номер: US20130190315A1
Принадлежит:

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation. 2. A compound according to claim 1 , wherein:{'sub': '2', 'Y is O or CH;'}{'sub': '2', 'X is O or CH;'}Q is selected from the group consisting of:{'sup': 'a', 'claim-text': {'sup': 2', '3', '4', '5', 'b', 'd', 'd', 'd', 'd', 'e', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'e', 'd', 'e', 'd', 'd', 'd', 'e', 'e', 'd', 'e', 'd', 'd, 'sub': 2', 'z', '2', 'z', '2', '2', '2', '2', '2', '2', '3, 'R, R, R, and R, are independently selected from the group consisting of hydrogen, halo, R, OR, O(CH)OR, O(CH)NRR, OC(O)R, SR, CN, NO, COR, CONRR, C(O)R, OC(O)NRR, NRR, NRC(O)R, NRC(O)R, NRC(O)NRR, S(O)R, S(O)R, NRS(O)R, S(O)NRR, and Nwhere z is 1, 2, or 3; and'}, 'i) imidazopyridinyl, methylimidazopyridinyl, indazolyl, pyrrolopyridinyl, pyrrolopyrazinyl, pyrazolopyridinyl, pyrazolopyrazinyl, and quinolinyl, each of which is optionally substituted with one to three R; wherein'}{'sup': 'a', 'claim-text': [{'sup': 2', '3', '4', 'b', 'd', 'd', 'd', 'd', 'e', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'd', 'e', 'd', 'e', 'd', 'd', 'd', 'e', 'e', 'd', 'e', 'd', 'd, 'sub': 2', 'z', '2', 'z', '2', '2', '2', '2', '2', '2', '3, 'R, R, and Rare independently selected from the group consisting of hydrogen, halo, R, OR, O(CH)OR, O(CH)NRR, OC(O)R, SR, CN, NO, COR, CONRR, C(O)R, OC(O)NRR, NRR, NRC(O)R, NRC(O)R, NRC(O)NRR, S(O)R, S(O)R, NRS(O)R, S(O)NRR, and Nwhere z is 1, 2, or 3; and'}, {'sup': 5', 'd, 'Ris selected from the group consisting of halo and OR;'}], 'ii) pyridinyl and piperidinyl, each of which is optionally substituted with one to three R; wherein'}{'sup': 6', '7, 'Rand Rtogether form oxo or an aldehyde protecting group;'}{' ...

Подробнее
25-07-2013 дата публикации

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Номер: US20130190491A1
Принадлежит: Gilead Sciences, Inc.

Compounds of formula I: 250.-. (canceled) This application claims benefit of U.S. Ser. No. 60/988,327, filed Nov. 15, 2007, which is herein incorporated by reference.The present invention relates to compounds, compositions and methods for the treatment of human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection. More specifically, the present invention provides novel inhibitors of the HIV integrase enzyme, pharmaceutical compositions containing such compounds and methods for using these compounds to reduce HIV replication and in the treatment of HIV infection.Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV), particularly the HIV-1 strain. Most currently approved therapies for HIV infection target the viral reverse transcriptase and protease enzymes. There is additionally one approved drug targeting gp41 to inhibit viral entry and one approved drug targeting the integrase enzyme. Within the reverse transcriptase inhibitor and protease inhibitor classes, resistance of HIV to existing drugs is a problem. Therefore, it is important to discover and develop new antiretroviral compounds.The present invention provides a novel series of compounds having inhibitory activity against HIV replication. Furthermore, representative compounds of the invention have activity as inhibitors in a cell-based HIV replication assay. Further objects of this invention arise for the one skilled in the art from the following description and the examples. The compounds of the present invention have an affinity for the HIV integrase enzyme. Therefore, the compounds of the invention may be used to inhibit the activity of HIV integrase and may be used to reduce HIV replication.One aspect of the invention provides an isomer, racemate, enantiomer or ...

Подробнее
25-07-2013 дата публикации

PROCESS TO PREPARE 6-CHLORO-3-AMINO-2-(2-HYDROXYPROPYL)-1-AZANAPHTHALENE

Номер: US20130190500A1
Принадлежит: Neuron Systems, Inc.

This invention relates to a process for the preparation of 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanapthalene. It comprises treating 6-chloro-3-pyridylium-2-ethoxycarbonyl-1-azanaphthanlene bromide with morpholine at about 80° C., followed by treating the product thereof with methylmagnesium chloride. 1. A process for the preparation of 6-chloro-3-amino-2-ethoxycarbonyl-1-azanaphthalene comprising treating 6-chloro-3-pyridylium-2-ethoxycarbonyl-1-azanaphthanlene bromide with morpholine at about 80° C.2. The process of further comprising treating ethyl pyridyliumpyruvate halide with 2-amino-5-chloro-benzaldehyde and pyridine at 80° C. under an inert atmosphere to yield 6-chloro-3-pyridylium-2-ethoxycarbonyl-1-azanapthalene halide.3. A process for the preparation of 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanapthalene comprising the process of followed by treating the product thereof with methylmagnesium chloride.4. A process for the preparation of 2-amino-5-chloro-benzalehyde comprising treating 5-chloro-2-nitrobenzaldehyde with hydrogen and 3% sulfided platinum. This application claims benefit of U.S. Provisional Application Ser. No. 61/569,358, filed on Dec. 12, 2011. The contents of the prior application are incorporated herein by reference.Compound A (6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene) is in early stage clinical trials for the treatment of macular degeneration.Although compound A can be readily prepared by those skilled in the art, more efficient synthetic routes are necessary for the production on a commercial scale. A highly efficient route to compound A is disclosed herein.This invention relates to a process for the preparation of 6-chloro-3-amino-2-ethoxycarbonyl-1-azanaphthalene, which comprises treating 6-chloro-3-pyridylium-2-ethoxycarbonyl-1-azanaphthanlene bromide with morpholine at about 80° C. This process may further comprise treating ethyl pyridyliumpyruvate halide with 2-amino-5-chloro-benzaldehyde and pyridine at 80° C. under ...

Подробнее